Chris Martin

Statistics

Publications

Citations

407

H-Index

Active since

2010

Affiliations

Poseida Therapeutics (United States)(Current)

University of Pennsylvania

University of California San Diego

The University of Texas MD Anderson Cancer Center

Sarah Cannon

Chris Martin is an author at Poseida Therapeutics (United States) specializing in hematologic malignancy therapy, relapsed multiple myeloma, and multiple myeloma.

Publications per year

2010–2023

Publications

IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25

Sven Létourneau, Ester M. M. van Leeuwen, Carsten Krieg et al. · Proceedings of the National Academy of Sciences · 2010 · 208 citations · Full text

Life Sciences, Cell Biology, Immunology +15

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin Costello, Adam D. Cohen, Krina K. Patel et al. · Blood · 2020 · 76 citations

Medicine, Hematology, Immunology +15

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Caitlin Costello, Tara Gregory, Syed Abbas Ali et al. · Blood · 2019 · 53 citations

Medicine, Hematology, Oncology +16

Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies

Adam D. Cohen, Alfred L. Garfall, Ahmet Doǧan et al. · Blood Advances · 2019 · 46 citations · Full text

Medicine, Oncology, Immunotherapy +12

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Bhagirathbhai Dholaria, Mehmet H. Kocoglu, Andrew Kin et al. · Blood · 2023 · 24 citations

Life Sciences, Hematology, Immunology +12

1–5 of 5